ClinicalTrials.gov
public full text
Public Domain
Phase 2a Study of HU6 in Subjects With Elevated Liver Fat and High BMI Volunteers
This is a Phase 2a, randomized, parallel-group, placebo-controlled, double-blind, repeated-dose study to evaluate the safety and efficacy of three oral dose levels of HU6 compared to placebo over the course of 61 days in subjects with high BMI and evidence of elevated liver fat.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Study of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-3655-001)#1060729
- Hepaxa Management of Non-alcoholic Fatty Liver Disease#1086189
- Efficacy and Safety of Picroliv in Patients With Non-Alcoholic Fatty Liver Disease#830879
- Relative Bioavailability Study of HU6#887861
- A Study of UBT251 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)#895892
Record · ID 1309622
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive